BERLIN – Elekta (EKTA-B.ST) today announced that Diagnostisch Therapeutisches Zentrum Berlin (DTZ) has treated the first patient in the world using Elekta Evo,* the company’s AI-powered adaptive CT-Linac. DTZ's first patient is a 62-year-old male who is receiving curative treatment for bladder cancer.

When delivering personalized radiation therapy, clinicians require high-quality images that allow them to visualize tumors and organs-at-risk. Evo addresses this with two essential features: Iris™ high definition, AI-enhanced imaging, which allows the visualization of target areas and critical structures with exceptional clarity, and Elekta ONE® | Online,** which brings distributed treatment planning, faster dose calculation and AI-driven automation for contouring and dose planning to streamline online and offline adaptive workflows.

Traditional surgery can be invasive and uncomfortable. For patients with bladder cancer who undergo bladder removal surgery, it can significantly impact their quality of life. Consequently, the patient chose to receive radiation therapy using Elekta Evo to treat his bladder cancer.

Dr. Matthias Lampe, Radiation Oncologist and partner at DTZ, says: “With Iris, CBCT image quality has improved significantly thanks to AI-enhanced image reconstruction. We now have much clearer visibility of targets and organs-at-risk, such as pelvic lymph nodes. This gives us greater confidence and saves time, and not only will it improve the quality of treatment but also patient comfort. Additionally, Evo will allow us to realize real-time treatment planning with online adaptive radiation therapy."

Offering online and offline plan adaptation, as well as improved image-guided radiation therapy (IGRT) treatments, Evo enables clinicians to choose the most suitable radiation therapy technique for each cancer patient’s case or treatment session and gives them the ability to adapt when they believe it will benefit the patient. Elekta Evo is a new addition to DTZ’s radiotherapy treatment offerings, which include five state-of-the-art linear accelerators and a range of our Elekta ONE software solutions.

"A long-time partner of Elekta, DTZ has a reputation for providing patients with the latest and most advanced diagnostic and therapeutic oncology technology available, and we’re proud that our solutions helped contribute to that success," says Gustaf Salford, Elekta President and CEO. "We’re committed to providing customers with the best imaging and treatment tools, and it is satisfying to hear – and see – how Evo is facilitating personalized radiotherapy for cancer patients. In the coming months, we look forward to even more sites commencing patient treatments with the system."

To learn more about Elekta Evo, visit: elekta.com/evo-dtz.

*Elekta Evo is CE marked and pending U.S. FDA 510(k) clearance with limited global availability.

**Elekta ONE is comprised of multiple Elekta solutions, some of which may not yet be available in all markets.

# # #

For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com  
Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time

About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on “X”, formerly known as Twitter.